Introduction
Peripheral nerve disease is a common neurological problem in patients infected with human immunode®ciency virus (HIV). Reported prevalence varies from 10 ± 50% (Dalakas and Pezeshkpour, 1988; Fuller et al, 1993) with an upward temporal trend in annual incidence rate (Bacellar et al, 1994 ). An even higher proportion of patients dying with AIDS had demonstrable histological abnormalities of their peripheral nerves (de la Monte et al, 1988; Fuller et al, 1990) .
Large nerve ®bres conduct nerve impulses more rapidly and their de®cits can best be quanti®ed by electromyography and nerve conduction studies. However, temperature sensation is mediated by small nerve ®bres (Light and Perl, 1984) and examination of thresholds for temperature perception can provide evidence of small-®bre neuropathy (Dyck et al, 1984; Fruhstorfer et al, 1976) . Clinically, the most common HIV related neuropathy is distal, symmetrical and predominantly sensory (Winer et al, 1992; Fuller et al, 1993) , sharing similarities with diabetic neuropathy (Brown and Asbury, 1984) . Small-®bre neuropathy can occur in both conditions, as evident by abnormalities of thermal sensitivity (Smith et al, 1990; Winer et al, 1992; Navarro and Kennedy, 1991; Claus et al, 1993) as well as pathological studies, where unmyelinated axon density was found to be low in patients with diabetes (Brown et al, 1976; Said et al, 1983) , and in those with AIDS (Fuller et al, 1991) . We set out to assess the prevalence of thermosensory abnormalities in patients infected with HIV infection.
Results
The 95th centile of the warm sensation (WS) of the forearm of normal controls was 2.48C above, and of the cold sensation (CS) was 1.68C below the baseline temperature of 328C. The 95th centile of the warm sensation (WS) of the foot was 5.98C above, and of the cold sensation (CS) was 3.98C below the baseline temperature, and these were taken as the upper limits of normal.
The co-ef®cient of variability (CV) of the mean of the WS and CS of the forearm were 24% and 21% and of the foot were 24% and 33% respectively.
Forty-seven of the 75 HIV positive subjects (62%) were asymptomatic and 28 (36%) had had at least one AIDS-de®ning illness prior to or within 30 days of their thermosensory tests. This included three patients with clinically evident peripheral neuropathy (PN), three with AIDS-Related Dementia (ARD) and two with both.
The results for WS and CS of the foot and forearm of the HIV negative controls, asymptomatic HIV positive patients, patients who developed their ®rst AIDS de®ning events excluding neurological abnormalities, and patients who developed PN and/or ARD are summarised in Table 1 .
The median CD4 cell count of the HIV positive subjects was 250/mm 3 (inter-quartile range 110 ± 340/mm 3 ). The relationship of thermosensory thresholds to patients' CD4 counts is shown in Table 2 .
Five patients had clinically evident peripheral neuropathy with symptoms mainly involving the feet, and one also had numbness of the ®ngers. All had abnormal WS and/or CS of the foot, and one had abnormal thermosensory thresholds of the forearm (see Table 3 ). One additional patient with asymptomatic HIV disease but a history of cerebral vascular accident had abnormal symptom and disability scores but normal thermosensory thresholds.
Forty-seven patients (63%) took zidovudine, 15 (20%) took didanosine (ddI) or zalcitabine (ddC) either alone or in combination with zidovudine, and four patients took dapsone. Thermosensory threshold data of those who did and did not take ddI or ddC are presented in Table 4 . Patients with PN/ ARD were excluded from this analysis, and the We were unable to demonstrate any effect of sex, age or BMI on thermosensory threshold abnormalities (P40.05 for all factors).
Discussion
Several factors affect the results of thermosensory testing, including the anatomical site tested, method of measurement and intra-or intersubject variability. The constant stimuli methods used exclude reaction time artefact and are more sensitive (Claus et al, 1990; Yarnitsky and Ochoa, 1990) and less dependent on the patient's concentration. The feet are more likely to be involved in early PN than the hands. The dorsum of the foot and the anterior aspect of the forearm were chosen because of ease of applying the thermode to a fairly¯at surface. In order to minimise intersubject variability, all tests were performed by one investigator. The reported intra-subject variability for thermosensory tests in the literature depends on the methodology used, and can vary between 5% (Janel et al, 1985) and 150% (Fagius and Wahren, 1981) . The CV of mean of our study range between 24 ± 33% for the foot, and 21 ± 24% for the forearm.
To our knowledge, thermosensory thresholds in HIV infected patients have been studied by three other groups (Winer et al, 1992; Berger et al, 1993; Smith et al, 1990) . Winer et al (1992) found the upper limits of the temperature threshold of the foot to be lower than in our study (e.g. warm sensation up to 1.08C for normal controls and 8.08C for those with neuropathy), which may re¯ect differences in methodology, since the thermode was placed on the plantar rather than the dorsal surfaces of the feet (Fowler et al, 1987) , thermal properties of the skin show marked variation between sites (Stevens et al, 1974) . Winer et al (1992) also preceded their tests by establishing an approximate value for the threshold before ®ne tuning the measurements, a step which we have omitted. Since patients demonstrate a learning process in thermosensory testing (Jamal et al, 1985) , this may contribute to the differences observed. Most importantly, their study may have used a different computer algorithm to that of TSA 2001 (Thermo Sensory Analyser from Medoc Ltd). Normative data obtained usind identical equipment showed a very similar upper limit of normal value to ourselves (Yarnitsky and Sprecher, 1994) .
All patients in our study with clinical PN showed WS and/or CS thresholds of the lower limbs above the 95th centile for controls, though the number of patients involved were small. One patient who had symptoms referable to the upper limb also had abnormal thresholds of the forearm. Furthermore, the median WS and CS of both sites were signi®cantly different from the controls and asymptomatic HIV positive patients. It may therefore be argued that the diagnosis of peripheral neuropathy should be questioned if a patient has no detectable thermosensory abnormalities especially of the foot, and this con®rms the results from previous studies (Winer et al, 1992; Berger et al, 1993) which found quantitative sensory testing to be a sensitive laboratory measure of neuropathy.
However, thermosensory abnormalities are not limited to those with clinical evidence of neuropathy since patients who experience their ®rst AIDS de®ning illness without clinical PN were also found to have signi®cantly higher median WS thresholds of both sites compared to controls. Even patients in the asymptomatic stage of HIV disease had signi®cantly abnormal thresholds. There is also a trend towards higher median CS with increasing severity of HIV disease, though not reaching statistical signi®cance for those without clinincal PN. This may be because sensation for cold is transmitted through larger, thinly-myelinated Ad ®bres, rather than the unmyelinated C ®bres responsible for warm sensation (Light and Perl, 1984) , and may therefore be affected later in the disease process. These ®ndings con®rm those of previous study where Winer et al also found abnormal thresholds in three of 10 patients without neuropathic symptoms or signs and in some patients without AIDS and AIDS-related complex (Winer et al, 1992) .
We wer not able to consistently demonstrate a relationship between thermosensory thresholds and CD4 counts due to the small sample size of the study.
At the moment we can only postulate on the signi®cance of these ®ndings. It is plausible that the processes causing clinical PN in HIV disease may occur very early, even in the asymptomatic stage. Electrophysiologic studies of patients without clinical PN showed primarily lower limb nerve conduction velocity abnormalities in symptomatic (CDC group IV) HIV positive patients when compared to seronegative controls (Smith et al, 1990; Fuller et al, 1991; Ronchi et al, 1992) , and a recent study showed signi®cantly lower sural nerve conduction velocities even in asymptomatic HIV patients with normal CD4 counts (Malessa et al, 1996) . Evoked potentials in HIV patients without neurological symptoms have also been studied. Auditory P300 latency was delayed in up to 30% of these patients (Birdsall et al, 1994) ; sensory evoked potential was abnormal in up to 10%, and some of them went on to develop clinical PN (Jabbari et al, 1993) . Quantitative sensory testing such as thermosensory thresholds may also be a useful, non-invasive test to detect early, small ®bre damage before clinically obvious peripheral neuropathy. We are undertaking a long term prospective study to evaluate the natural history and predictive value of abnormal thermosensory thresholds in the subsequent development of HIV related neuropathy.
This study could not con®rm or refute a relationship between taking known neurotoxic antiretroviral drugs such as ddI or ddC and changes in thermosensory thresholds, although a longer follow-up period and larger cohort may demonstrate such an effect. An early predictor of peripheral neuropathy would be an invaluable tool in the management of drug related neural toxicity in HIV infected patients.
Materials and methods

Equipment
A Thermo Sensory Analyser (TSA 2001: from Medoc Ltd) was used to measure the threshold for warm sensation (WS) and cold sensation (CS). A small thermode was attached to the patient and capable of heating and cooling the skin from the predetermined baseline temperature of 328C. The method chosen for this study is one of`Constant Stimuli Methods' called the`Staircase Test' (Claus et al, 1990) , where the thermode temperature was increased or decreased automatically according to the subject's response. The Thermode was placed on the dorsum of the right foot and anterior aspect of the right wrist in all cases.
Subjects
Patients with diabetes, vitamin B12 de®ciency or family history of neuropathy were excluded from the study. Patients whose alcohol intake was greater than 40 units per week (one unit of alcohol is equivalent to one glass of wine, half pint of beer or one shot of spirit) or on neurotoxic drugs other than antiretroviral therapy were also excluded.
Informed consent was obtained from the controls and patients and the study was approved by the local ethical committee.
Patients were all HIV antibody positive and recruited from two dedicated outpatient clinics in Birmingham (The General Hospital and Heartland's Hospital), UK, between May 1993 and December 1995. Seventy-®ve patients were recruited comprising three women and 72 men; 65 were men who had sex with men, six came from sub-Saharan Africa and four acquired HIV infection heterosexually. There were no injecting drug users in this cohort. The median age was 35 (inter-quartile range 29 ± 43).
All patients were questioned about neurological symptoms and received a standardised neurological examination. Standardised neurological symptom and disability scores (Dyck et al, 1980; Winer et al, 1992) were used and patients who scored more than two on the symptom score and more than six on the disability score were considered abnormal and de®ned as having clinical peripheral neuropathy. Abbreviated Neuropsychiatric AIDS Rating Scale (NARS) devised by Price and Brew (1988) was used and patients scored 51 was considered to have dementia. Thermosensory tests were performed in all patients and the diagnosis of clinical peripheral neuropathy was made without the results of thermosensory tests. CD4 lymphocyte counts were performed within 30 days of thermosensory measurements.
In order to assess the effect of didanosine (ddI) or zalcitabine (ddC), thermosensory thresholds were compared between patients who took ddI and/or ddC and those who did not, after matching for CD4 counts.
Data on age was available in all patients, and data on Body Mass Index (BMI) in 56 of the 75 patients.
Controls
Controls were recruited from presumed HIV negative staff and male patients who attended the GU clinic for unrelated conditions and had a negative HIV antibody test. Subjects with past or present history of neurological diseases were excluded. Forty controls were recruited comprising 33 heterosexual males, three homosexual males (both HIV negative) and four females. The median age was 33.5 (inter-quartile range 28 ± 45).
Co-ef®cient of variability (CV) of the mean Data from ®ve controls and 15 patients who had a repeat test at the same session were used to measure CV of the mean of the thermosensory test. All tests were performed by one investigator (MH).
Statistics
Computer software package Minitab version 11 was used for statistical analysis. Mann ± Whitney U test was used for non-parametric comparison of two groups; stepwise multiple regression was used to assess the effects of sex, age and BMI on themosensory thresholds; P value of 50.05 was considered signi®cant.
